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Abstract The selective binding of serum amyloid P component
(SAP) to proteins in the pathological amyloid cross-L fold
suggests a possible chaperone role. Here we show that human
SAP enhances the refolding yield of denatured lactate dehy-
drogenase and protects against enzyme inactivation during
agitation of dilute solutions. These effects are independent of
calcium ions and are not inhibited by compounds that block the
amyloid recognition site on the B face of SAP, implicating the A
face and/or the edges of the SAP pentamer. We discuss the
possibility that the chaperone property of SAP, or its failure,
may contribute to the pathogenesis of amyloidosis.
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1. Introduction
The mechanisms by which protein molecules attain their
biologically active conformations are of great fundamental
interest, and recognition of the role of molecular chaperones
in these processes within the cell has been a critical contribu-
tion to cell biology [1,2]. The recent appreciation that aberra-
tions of protein folding are responsible for a number of hu-
man diseases, has focused additional attention in this area [3].
In particular, the propensity for a group of otherwise unre-
lated, soluble, globular proteins to aggregate and deposit ex-
tracellularly as amyloid ¢brils is important because amyloido-
sis is a feature of Alzheimer’s disease, type 2 diabetes and the
prion diseases, as well as the fatal, acquired and hereditary,
systemic amyloidoses [4].
Serum amyloid P component (SAP) is a non-¢brillar plas-
ma glycoprotein that undergoes speci¢c calcium dependent
binding to all types of amyloid ¢brils, even though it shows
no a⁄nity for the same proteins in their native state [5]. Bind-
ing of SAP stabilizes amyloid ¢brils in vitro [6] and amyloid
deposition is reduced and delayed in SAP knockout mice [7].
This capacity of SAP to recognize misfolded proteins of the
¢brils resembles the behavior of molecular chaperones and
suggested to us that SAP may a¡ect protein folding.
The SAP molecule is an oligomer of ¢ve identical subunits
non-covalently associated in a disc-like particle with cyclic
pentameric symmetry, diameter 100 Aî , and depth 35 Aî . The
atomic resolution three-dimensional (3D) structure of human
SAP reveals a L-sheet sandwich fold for the protomer, with
£attened jelly roll topology, and with the two calcium ions,
required for ligand binding, bound 4 Aî apart by loop side
chains that congregate on one face of the sheet [8]. One sur-
face of the pentamer carries the ¢ve double calcium sites on
the binding, B, face, while the other, A, face is characterized
by ¢ve K-helices. The calcium dependence of SAP binding to
amyloid ¢brils [9] and the fact that the cyclic pyruvate acetal
of galactose, 4,6-O-(1-carboxyethylidene)-L-D-galactopyrano-
side (MOLDG), that binds into the double calcium site dis-
places SAP from amyloid [10], indicate that this is the amyloid
recognition site.
2. Materials and methods
SAP and the closely related pentraxin, C-reactive protein (CRP),
were puri¢ed as described previously [11,12]. SAP was stored at 56
mg/ml in 10 mM Tris/HCl bu¡er pH 8.0 containing 140 mM sodium
chloride and 10 mM EDTA. CRP was stored at 4.4 mg/ml in 10 mM
Tris/HCl bu¡er pH 8.0 containing 140 mM sodium chloride and
2 mM calcium chloride. Lactate dehydrogenase (LDH) from Bacillus
stearothermophilus was purchased from Porton Products, or Sigma,
UK. SAP was immobilized on cyanogen bromide activated Sepharose
as described previously [13] to provide V1 mg SAP/ml of settled
matrix. LDH was denatured by incubation for 2 h at room temper-
ature in 4.2 M guanidine hydrochloride in 50 mM MOPS/KOH, 150
mM NaCl, 10 mM L-mercaptoethanol, pH 7.0. Refolding was initi-
ated at 25‡C by a 200-fold dilution of the denatured LDH to a ¢nal
protomer concentration of between 40 and 70 nM in the same bu¡er
but without guanidine and L-mercaptoethanol. The e¡ects were tested
of the presence during refolding of SAP, or CRP, with or without
calcium ions, MOLDG, or dAMP. In pilot experiments the refolding
cocktail included the LDH assay substrates and activity was moni-
tored continuously. In follow-up experiments LDH activity was as-
sayed at discrete time intervals by diluting 900 Wl aliquots of the
refolding mixture with 100 Wl of MOPS bu¡er including 100 mM
pyruvate and 2 mM L-NADH, and monitoring absorption at 340
nm for 60 s at 25‡C. Isolated human SAP rapidly autoaggregates in
the presence of calcium ions and this was monitored by light scatter-
ing at 500 nm excitation and emission. The concentration of residual
soluble SAP was determined by absorbance at 280 nm (E(1%, 1 cm)
= 17.1).
To induce inactivation by agitation, 500 Wl of 50 nM LDH in
MOPS/NaCl bu¡er pH 7.0, in a 1.5 ml plastic microfuge tube, were
rotated on a blood tube mixer at 20 rpm. Aliquots (10 Wl) were
removed at intervals for estimation of remaining LDH activity as
described above. SAP, or CRP, with or without calcium ions and
MOLDG, were included in the sample at the start of mixing.
3. Results and discussion
LDH from B. stearothermophilus is denatured by 4 M gua-
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nidine hydrochloride to a state showing no secondary struc-
ture [14]. Only 3^6% of active dimeric enzyme was slowly
regained by diluting out the denaturant as described. Recov-
ery rose to about 8% if L-mercaptoethanol was included in the
refolding step, but it was usually omitted to avoid reduction
of the single intrachain disulphide bridge within each SAP
protomer. Addition of SAP to the refolding solution markedly
enhanced the yield of active LDH. A typical experiment,
shown in Fig. 1, included 400 nM SAP (with respect to pen-
tamer), 3 mM calcium ions and 40 nM LDH. In the same
conditions, inclusion of 2 mM MOLDG, which blocks the
calcium dependent ligand binding site of SAP and also the
calcium dependent aggregation of SAP, did not reduce the
SAP induced enhancement of LDH refolding and in fact in-
creased the yield.
No change in the refolding yield was observed when CRP
was included in place of SAP at 0.4 or 2.0 WM with respect to
pentamers, representing a 10^40-fold excess over LDH sub-
units (Fig. 1). This powerful control demonstrates the highly
speci¢c nature of SAP enhanced refolding of LDH, since CRP
and SAP share 52% sequence identity, a common subunit fold
and pentameric oligomeric structure and both bind calcium
ions in a similar way, although in contrast to human SAP,
CRP does not autoaggregate in the presence of calcium [15].
Increasing the concentration of SAP to 2 WM increased the
refolding yield but this did not exceed the value of V25%
shown with MOLDG in Fig. 1. The e¡ective concentration
and form of SAP in these experiments was di⁄cult to quantify
because of the severe calcium dependent aggregation of SAP.
Light scattering measurements showed that even at SAP con-
centrations as low as 100 nM some aggregation occurred im-
mediately after mixing with 3 mM calcium ions (Fig. 2). At
2 WM SAP we estimate that only 10% remained in solution.
These results are likely to change with time after mixing and
suggest that the protein does not exhibit a simple solubility
limit.
The enhanced refolding of LDH was also observed in the
absence of calcium ions (Fig. 3) where SAP is highly soluble,
but even at SAP concentrations as high as 4 WM the maximal
enhancement (V25%) was never exceeded. SAP immobilized
by covalent attachment to Sepharose beads, so that calcium
induced aggregation was prevented, also increased the yield of
refolding LDH in the presence of calcium ions.
The calcium induced aggregation of SAP is apparently due
to binding of carboxylate ligands on the A face by the calcium
dependent ligand binding sites on the B face, as we have
previously reported [5,16], leading to A:B face stacking of
pentamers. The MOLDG concentration used here completely
inhibits aggregation (KdV0.1 mM), probably by occupying
these sites, and the SAP remains in solution as free individual
pentamers [17]. The enhancement of SAP induced refolding
yield produced in some experiments by addition of MOLDG
(Fig. 1A) presumably resulted from increased solubility of
SAP with more of it therefore readily available for interaction
with LDH folding intermediates. Although SAP clearly pro-
moted refolding in the absence of calcium, indicating that the
B face calcium dependent ligand binding sites are apparently
not involved, it is conceivable that an inhibitory action of
Fig. 1. Reactivation of chemically denatured LDH (40 nM) in the
absence (8) or presence (7) of 400 nM SAP, 400 nM CRP (E),
2 mM MOLDG (b), or SAP and MOLDG (a) in 50 mM MOPS^
KOH pH 7.0 bu¡er containing (A) 3 mM CaCl2 or (B) 150 mM
NaCl and 7 mM CaCl2.
Fig. 2. Concentration dependence of SAP aggregation induced by
calcium ions measured by light scattering at an excitation and emis-
sion wavelength of 500 nm, at room temperature in 50 mM MOPS^
KOH pH 7.0 with 2 mM EDTA (8), 3 mM CaCl2 (7), 7 mM
CaCl2 (E), or 3 mM CaCl2 and 140 mM NaCl (a).
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MOLDG could be masked by its capacity to increase the
concentration of soluble SAP in the presence of calcium.
However, if the calcium site in SAP did contribute to the
refolding enhancement, and the Kd of the SAP^MOLDG in-
teraction was in the region of 0.1 mM, then in the mixture of
400 nM SAP/3 mM calcium/2 mM MOLDG (Fig. 1) the e¡ect
of the SAP calcium site on LDH refolding would be attribut-
able to just 5% of the SAP (20 nM). It is unlikely that the
calcium site could have such potency as we have determined
that the 200 nM soluble SAP that remains on mixing 2 WM
SAP with 3 mM calcium is less e¡ective in enhancing LDH
refolding. Furthermore we found that SAP in the absence of
calcium enhanced the refolding yield of LDH to a similar
extent to calci¢ed SAP at the same concentration in the pres-
ence of MOLDG. The e¡ect of MOLDG on SAP solubility
therefore seems to provide a good explanation for the appar-
ent increase in activity, and the increased stability of SAP
conferred by the bound ligand [6] could provide additional
bene¢t to the complex.
Calcium dependent aggregation of SAP is also prevented by
the ligand, dAMP, which, at appropriate molar excess is
bound by SAP and then induces formation of the B:B face
decamers that we have previously characterized [18]. Under
these conditions, both with 4 WM SAP, 5 mM dAMP and
7 mM calcium in the refolding mixture together with LDH
and substrates (Fig. 4), and when activity was assayed sepa-
rately after refolding (Table 1), there was no di¡erence in
enhancement of refolding compared to control mixtures with-
out dAMP.
Gentle agitation of LDH at 50 nM in the presence of 3 mM
calcium ions for 30 min eliminated about 75% of the enzyme
activity (Table 2). Similar but less dramatic inactivation also
took place in gently stirred solutions. It is likely that physical
forces such as shear at the air/liquid or liquid/container inter-
face, foaming or cavitation are responsible for this loss of
activity. Inclusion of L-mercaptoethanol does not protect
LDH activity in these conditions, suggesting that cysteine ox-
idation is not involved. However, in the presence of V4 WM
immobilized SAP or 500 nM free SAP (with respect to pen-
tamer) only 25% of the LDH activity was lost irrespective of
the presence or absence of 2 mM MOLDG.
Molecular chaperones function by binding to aggregation-
prone folding intermediates and we presume that SAP enhan-
ces the e⁄ciency of LDH refolding by similarly interacting
with intermediates on the refolding landscape to increase the
£ux through productive routes [19]. The e¡ect of SAP is sat-
urable, with a maximum of 25% regain of activity in the
present conditions. This might re£ect di¡erential rates of par-
titioning of intermediates between states that interact with
SAP and others. A small proportion clearly proceed directly
to the native state but the majority go to an inactive misfolded
product. SAP might bind to a misfolded state and enhance
LDH folding by removing species capable of forming an un-
productive dimer or act in a more direct way by enabling the
formation of productive species. The parallel we drew between
Fig. 3. Reactivation of chemically denatured LDH (40 nM) in the
presence (7) or absence (8) of 400 nM SAP in 50 mM MOPS^
KOH pH 7.0.
Fig. 4. Reactivation of chemically denatured LDH (70 nM) in the
absence (dashed line, long dashes) or presence (solid line) of 4 WM
SAP, 5 mM dAMP (dot dashed line), or SAP and dAMP (dashed
line, short dashes) in 50 mM MOPS^KOH pH 7.0, 150 mM NaCl,
7 mM CaCl2 bu¡er. Activity regain was monitored continuously by
absorbance change at 340 nm at room temperature.
Table 1
E¡ect of dAMP on reactivation of LDH after guanidine dilution in
presence of SAP
Reagents present during
refolding
% Initial LDH activity
(mean (S.D.))
LDH alone 2.28 (0.78)
LDH+SAP 8.61 (0.45)
LDH+SAP+dAMP 9.33 (0.21)
LDH+dAMP 2.24 (0.56)
LDH (50 mM) was refolded from guanidine in the presence of
3 mM calcium, 500 mM SAP and 5 mM dAMP and restored activ-
ity determined. n = 3.
Table 2
E¡ect of immobilized SAP on loss of LDH activity during mixing
Residual LDH activity
LDH without mixing 96.8
LDH alone 26.0
LDH+Sepharose-SAP 74.9
LDH+Sepharose-SAP+MOLDG 65.4
LDH+MOLDG 26.9
LDH (50 mM) was mixed for 30 min in the presence of 3 mM cal-
cium, V4 WM SAP immobilized covalently on Sepharose and 2 mM
MOLDG, then assayed for residual activity.
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recognition of the protein misfold of amyloid and protein
folding intermediates would favor models in which the SAP
interacts with misfolding species. However, we have shown
that the site on SAP most likely to be involved in amyloid
recognition, can be blocked by MOLDG without any inhib-
itory e¡ect on the folding enhancement of LDH. The site can
also be blocked by formation of B:B face decamers by inter-
action with dAMP without e¡ect on the LDH refolding phe-
nomenon. Furthermore, the refolding reaction can proceed in
the absence of calcium, which is absolutely required for amy-
loid binding. We therefore conclude that this site is not in-
volved in the folding enhancement process, and presume that
the A face and/or ’edge’ regions of the pentameric disc are
involved.
It has lately become clear that even proteins unrelated to in
vivo amyloidogenesis can be induced by suitable denaturation
protocols in vitro to adopt the amyloid cross-L fold and to
aggregate as typical amyloid ¢brils [20^23]. This highlights the
mysterious fact that only about 20 diverse and unrelated pro-
teins are known to form amyloid ¢brils in vivo. Here we
demonstrate that for LDH only gentle agitation is su⁄cient
to initiate unfolding reactions that must be a general feature
in the production of amyloidogenic precursors. Although
LDH is not itself an amyloid protein, our observations are
reminiscent of results obtained with AL1^42, the major amy-
loid ¢bril protein in Alzheimer’s disease. This spontaneously
forms amyloid ¢bers in physiological, non-denaturing, solvent
conditions in vitro. SAP binds the mature ¢bers in a calcium
dependent reaction but SAP is also reported to retard ¢ber
formation in a calcium independent reaction [24]. Since bind-
ing of SAP stabilizes amyloid ¢brils in vitro [6] and partici-
pates in pathogenesis of amyloidosis in vivo [7], we wonder
whether display by misfolding amyloidogenic precursor pro-
teins of ligands recognized by the calcium dependent binding
site of SAP may contribute to their clinical amyloidogenicity.
In contrast, other proteins, not recognized by SAP in this
way, may undergo productive folding interactions with SAP,
or at least not be trapped or enabled by calcium dependent
SAP binding to persist in the pathological conformation that
causes amyloid disease.
An alternative scenario is suggested by the protection con-
ferred by SAP against agitation induced denaturation of
LDH. Here there is gradual production of misfolded species
and mere binding of SAP to these would not be expected to
prevent overall loss of enzyme activity unless such loss de-
pended on a nucleated aggregation process, as occurs in ex-
perimental amyloid ¢brillogenesis in vitro [21]. SAP may
therefore have a surveillance role in vivo, binding to misfolded
species and preventing the seeding of larger aggregates. The
primary driving force towards clinical amyloidosis would then
be the inherent instability that is now recognized as a common
feature of amyloidogenic precursor proteins [25,26]. This may
¢rst overwhelm the normal productive folding role of SAP,
and subsequent calcium dependent binding of SAP to mature
¢brils could then stabilize and protect them from degradation
[6]. Whatever the underlying mechanisms, the present obser-
vations support our novel approach to therapy of amyloido-
sis, which is about to be evaluated clinically, using a drug that
inhibits SAP binding and dissociates it from the deposits [27].
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